Literature DB >> 11078367

Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate.

S A Douglas1, D J Ashton, C F Sauermelch, R W Coatney, D H Ohlstein, M R Ruffolo, E H Ohlstein, N V Aiyar, R N Willette.   

Abstract

The observation that the novel G-protein-coupled receptor (GPCR) GPR14 and its cognate ligand, urotensin-II (U-II), are expressed within the mammalian vasculature raises the possibility that they may influence cardiohemodynamic homeostasis. To this end, this study examined the vasoactive properties of U-II in rodents, dogs and primates. In vitro, human U-II was a sustained vasoconstrictor with a potency (pD2s < or = 9) approximately an order of magnitude greater than that seen with endothelin-1 (ET-1), making it one of the most, if not the most, potent mammalian vasoconstrictor identified to date. However, in vitro responses exhibited significant anatomical and/or species-dependency, that is, human U-II was a selective 'aorto-coronary' vasoconstrictor in rats and dogs, inactive in mice and contracted all primate arteries studied. In vivo, this peptide evoked a complex, dose-dependent hemodynamic response in the anesthetized primate, culminating in severe myocardial depression and fatal circulatory collapse. As such, U-II may represent a novel neurohumoral regulator of mammalian cardiovascular physiology and pathology in particular disorders characterized by aberrant vascular smooth muscle and/or myocardial function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11078367     DOI: 10.1097/00005344-200036051-00051

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat.

Authors:  M R MacLean; D Alexander; A Stirrat; M Gallagher; S A Douglas; E H Ohlstein; I Morecroft; K Polland
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).

Authors:  Valeria Camarda; Martina Spagnol; Wei Song; Raffaella Vergura; Adelheid L Roth; Jonathan P Thompson; David J Rowbotham; Remo Guerrini; Erika Marzola; Severo Salvadori; Paolo Cavanni; Domenico Regoli; Stephen A Douglas; David G Lambert; Girolamo Calò
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 3.  Is urotensin-II the new endothelin?

Authors:  Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

4.  Human urotensin-II is a potent spasmogen of primate airway smooth muscle.

Authors:  D W Hay; M A Luttmann; S A Douglas
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

5.  Desensitisation of native and recombinant human urotensin-II receptors.

Authors:  Madura S Batuwangala; Girolamo Calo; Remo Guerrini; Leong L Ng; John McDonald; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-13       Impact factor: 3.000

6.  Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure.

Authors:  Ludger Leifeld; Christoph Clemens; Jörg Heller; Jonel Trebicka; Tilman Sauerbruch; Ulrich Spengler
Journal:  Dig Dis Sci       Date:  2009-07-07       Impact factor: 3.199

7.  State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells.

Authors:  Eugen Brailoiu; Xiaohua Jiang; G Cristina Brailoiu; Jun Yang; Jaw Kang Chang; Hong Wang; Nae J Dun
Journal:  Peptides       Date:  2008-01-31       Impact factor: 3.750

8.  Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.

Authors:  David Chatenet; Thi-Tuyet M Nguyen; Myriam Létourneau; Alain Fournier
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-02       Impact factor: 5.555

9.  Endogenous urotensin II selectively modulates erectile function through eNOS.

Authors:  Roberta d'Emmanuele di Villa Bianca; Emma Mitidieri; Ferdinando Fusco; Elena D'Aiuto; Paolo Grieco; Ettore Novellino; Ciro Imbimbo; Vincenzo Mirone; Giuseppe Cirino; Raffaella Sorrentino
Journal:  PLoS One       Date:  2012-02-02       Impact factor: 3.240

10.  Is plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome?

Authors:  Magdalena Babińska; Michał Holecki; Fryderyk Prochaczek; Aleksander Owczarek; Danuta Kokocińska; Jerzy Chudek; Andrzej Więcek
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.